Aclaris Therapeutics, Inc (ACRS)

Etorro trading 970x250

About Aclaris Therapeutics, Inc

Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound that is in phase 2 clinical trial for the treatment of moderate to severe rheumatoid arthritis, COVID-19, and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is in phase 2a clinical trial to treat moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound for the treatment for psoriasis and/or inflammatory bowel disease, as well as A-101 45% topical solution to treat common warts. It also provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Address: 640 Lee Road, Wayne, PA, United States, 19087

Aclaris Therapeutics, Inc News and around…

Latest news about Aclaris Therapeutics, Inc (ACRS) common stock and company :

Hedge Funds Are Crazy About Aclaris Therapeutics, Inc. (ACRS)
12 Oct, 2021 Yahoo! Finance

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

The Math Shows XPH Can Go To $72
07 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $71.78 per unit.

ACRS Crosses Above Key Moving Average Level
24 Sep, 2021 FinancialContent

In trading on Friday, shares of Aclaris Therapeutics Inc (ACRS) crossed above their 200 day moving average of $18.27, changing hands as high as $18.58 per share. Aclaris Therapeutics Inc shares are currently trading trading flat on the day..

Top Biotech Stocks for Q4 2021
20 Sep, 2021 Yahoo! Finance

The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aclaris Therapeutics, Inc. – ACRS
20 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Thursday's Pre-Market Session
16 Sep, 2021 FinancialContent

Gainers Leap Therapeutics (NASDAQ:LPTX) stock rose 32.64% to $2.56 during Thursday's pre-market session. The ...

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
03 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Aclaris Therapeutics (ACRS) Shares Cross Above 200 DMA
01 Sep, 2021 FinancialContent

In trading on Wednesday, shares of Aclaris Therapeutics Inc (ACRS) crossed above their 200 day moving average of $17.14, changing hands as high as $18.00 per share. Aclaris Therapeutics Inc shares are currently trading up about 6.2% on the day..

Looking into Aclaris Therapeutics's Return on Capital Employed
27 Aug, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, Aclaris Therapeutics's (NASDAQ:ACRS) reported sales totaled $1.82 ...

Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
27 Aug, 2021 FinancialContent
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
26 Aug, 2021 FinancialContent
The 9.4% return this week takes Aclaris Therapeutics' (NASDAQ:ACRS) shareholders one-year gains to 510%
25 Aug, 2021 Yahoo! Finance

Some Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders are probably rather concerned to see the share price fall...

12 Health Care Stocks Moving In Monday's After-Market Session
23 Aug, 2021 FinancialContent

Gainers Cara Therapeutics (NASDAQ:CARA) stock rose 22.54% to $17.5 during Monday's after-market session. Trading volume for this ...

Should You Buy Aclaris Therapeutics (ACRS) Ahead of Earnings?
05 Aug, 2021 Yahoo! Finance

Aclaris Therapeutics (ACRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Implied IWV Analyst Target Price: $287
05 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 3000 ETF (IWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $286.74 per unit.

Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
05 Aug, 2021 FinancialContent
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
30 Jul, 2021 Yahoo! Finance

Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Therapeutics Breaks Below 200-Day Moving Average - Notable for ACRS
15 Jul, 2021 FinancialContent

In trading on Thursday, shares of Aclaris Therapeutics Inc (ACRS) crossed below their 200 day moving average of $15.28, changing hands as low as $14.89 per share. Aclaris Therapeutics Inc shares are currently trading down about 5.3% on the day..

Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021
08 Jul, 2021 FinancialContent
10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman
06 Jul, 2021 Yahoo! Finance

In this article, we will discuss the 10 best pharmaceutical stocks to buy according to billionaire Joseph Edelman. If you want to skip our detailed analysis of Edelman’s history, investment philosophy, and hedge fund performance, go directly to the 5 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman. Joseph Edelman was born in […]

Hedge Funds Have Never Been This Bullish On Aclaris Therapeutics, Inc. (ACRS)
06 Jul, 2021 Yahoo! Finance

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of March 31st. The results of that effort will be put on display in this article, as […]

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
15 Jun, 2021 FinancialContent

Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to ...

12 Health Care Stocks Moving In Thursday's Intraday Session
10 Jun, 2021 FinancialContent

Gainers NuCana (NASDAQ:NCNA) shares moved upwards by 16.17% to $3.16 during Thursday's regular session. NuCana's ...

Aclaris Announces Pricing of Public Offering of Common Stock
09 Jun, 2021 FinancialContent
12 Health Care Stocks Moving In Wednesday's Intraday Session
09 Jun, 2021 FinancialContent

Gainers Aethlon Medical (NASDAQ:AEMD) shares moved upwards by 347.96% to $9.9 during Wednesday's regular session. As ...

Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
09 Jun, 2021 Yahoo! Finance

Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.

The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US
09 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

75 Biggest Movers From Yesterday
09 Jun, 2021 FinancialContent

Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares surged 85.8% to close at $22.15 on Tuesday amid increased retail ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
08 Jun, 2021 FinancialContent

Gainers Aethlon Medical (NASDAQ:AEMD) stock increased by 19.9% to $2.65 during Tuesday's after-market session. Today's trading volume ...

Aclaris Announces Proposed Public Offering of Common Stock
08 Jun, 2021 FinancialContent

Aclaris Therapeutics, Inc (ACRS) is a NASDAQ Common Stock listed in , ,

970x250